Handelsavisen
prelaunch
Companies Healthcare LEEF.CD
LE
LEEF.CD Pharmaceuticals

Leef Brands Inc

$0,22
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
-40,4 %
ROE
-748,1 %
Net margin
-70,0 %
Debt / equity
28,43
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Business description not yet wired for this issuer.

Business. Leef Brands Inc (LEEF.CD) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm operates within the Healthcare sector, specifically focusing on product sales within the Pharmaceuticals industry. No specific operating segments or geographic breakdowns are provided in the available data. The company is identified by the ticker symbol LEEF.CD.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-748,1 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning LEEF.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to LEEF.CD. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Leef Brands Inc (LEEF.CD) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm operates within the Healthcare sector, specifically focusing on product sales within the Pharmaceuticals industry. No specific operating segments or geographic breakdowns are provided in the available data. The company is identified by the ticker symbol LEEF.CD.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    Leef Brands Inc is a company in the Pharmaceuticals & Medical Research industry, primarily engaged in the development and distribution of personal care products within the healthcare sector.

    Leef Brands Inc is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, with a high confidence level of 0.92 according to verified market data.

    Leef Brands Inc has a highly leveraged capital structure, with a debt-to-equity ratio of 28.43, indicating a significant reliance on debt financing. The company's liquidity position is rated as medium, with a current ratio of 0.55, suggesting limited short-term liquidity to cover immediate liabilities. Free cash flow is negative at -$6.82 million, and operating cash flow is only $162,080, further highlighting the company's cash flow constraints.

    Profitability metrics are severely negative, with a return on equity of -7.48 and a return on assets of -0.12, both well below the typical thresholds for pharmaceutical companies. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets.

    The company's revenue is concentrated in a single business segment, as disclosed in its financials, with no geographic diversification provided in the available data. This lack of diversification increases exposure to market-specific risks.

    The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the outlook. Historical financial data shows a net loss of $5.54 million, and the company reported negative operating income of $3.20 million, indicating a lack of operational profitability.

    Risk factors include a high debt load and negative net cash position, which could limit the company's ability to invest in growth or respond to market challenges. The risk assessment indicates a low potential for dilution, but the company's financial instability could lead to future capital-raising activities that may involve equity dilution.

    Recent events include the filing of financial statements that highlight the company's significant losses and liquidity constraints. No recent earnings call transcripts or major corporate announcements are available in the provided data.

    - Leef Brands Inc is highly leveraged, with a debt-to-equity ratio of 28.43, indicating a significant reliance on debt financing. - The company is not generating returns for its shareholders, with a return on equity of -7.48 and a return on assets of -0.12. - Leef Brands Inc has a negative free cash flow of -$6.82 million and a weak operating cash flow of $162,080, indicating cash flow constraints. - The company's financial instability and high debt load pose significant risks to its future operations and growth potential. - There is no geographic or segment diversification disclosed, increasing the company's exposure to market-specific risks.

    Key takeaways
    • Leef Brands Inc (LEEF.CD) is a pharmaceutical company engaged in pharmaceuticals and medical research.
    • The firm operates within the Healthcare sector, specifically focusing on product sales within the Pharmaceuticals industry.
    • No specific operating segments or geographic breakdowns are provided in the available data.
    • The company is identified by the ticker symbol LEEF.CD.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 5

    Revenue grew 22.1% year-over-year to $34.8 million, demonstrating significant top-line expansion momentum.

    Net income improved 28.4% year-over-year, indicating a meaningful reduction in the company's operating losses.

    Free cash flow improved 42.5% year-over-year, suggesting better cash generation despite ongoing negative flows.

    Long-term debt decreased significantly from $23.1 million to $12.6 million, strengthening the balance sheet position.

    The company achieved a 45.8% revenue CAGR over four years, highlighting strong historical growth trajectory.

    BEAR CASE · 3

    The debt-to-equity ratio of 28.43 is in the bottom quartile, signaling extreme financial leverage risk.

    Return on equity of -7.48% is in the bottom quartile, indicating poor capital utilization efficiency.

    The company faces high credit risk, posing a significant threat to its financial stability and operations.

    In focus — financials by report

    Valuation FY

    Market price
    $0,22
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $740.4k
    Net cash
    -$21.0M
    Current ratio
    0.6
    Debt / equity
    28.4
    ROA
    -12.2%
    ROE
    -7.5%
    Cash conversion
    -3.0%
    CapEx / revenue
    -41.2%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-40,4 %Bottom quartile
    Net Margin-70,0 %Bottom quartile
    ROE-748,1 %Bottom quartile
    Capex / Rev-41,2 %Bottom quartile
    D/E28,43Bottom quartile
    Cash Conv-0,03Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Leef Brands Inc Market data — financials · 2026-05-28

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    LEEF.CDCanonical
    — · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage